Alimera sciences announces preliminary top-line results for fourth quarter and full-year 2020

Atlanta, jan. 19, 2021 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) (alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces preliminary consolidated net revenue for the fourth quarter of 2020 in excess of $13.5 million and annual 2020 consolidated net revenue in excess of $50.5 million. alimera anticipates that cash on december 31, 2020 will be $11.2 million compared to $11.3 million on september 30, 2020.
ALIM Ratings Summary
ALIM Quant Ranking